You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 94 No. 3, March 1976 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL SCIENCES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Carcinoembryonic Antigen

Its Role in the Evaluation of Intraocular Malignant Tumors

Joseph B. Michelson, MD; Norman T. Felberg, PhD; Jerry A. Shields, MD

Arch Ophthalmol. 1976;94(3):414-416.


Abstract

• Plasma carcinoembryonic antigen (CEA) was studied in 60 patients with histologically confirmed intraocular neoplasms including 56 malignant melanomas of the uvea and four metastatic tumors to the choroid. While 45% of the patients with primary uveal melanomas, as well as 75% of the patients with metastatic disease demonstrated elevated plasma CEA levels, both patients who exhibited metastatic lesions of entodermal origin demonstrated plasma CEA values that clearly fell into a separate, highly elevated category, consistent with metastatic disease or pancreatic or colorectal carcinoma. Thus, in the patient seen with a nonpigmented choroidal mass that may represent either a choroidal hemangioma, amelanotic melanoma, or metastatic tumor, plasma CEA levels may be useful in the differential diagnosis. If the clinician suspects a metastatic tumor from an occult primary site, highly elevated CEA levels may indicate that the lesion is of entodermal origin.



Author Affiliations

From the Department of Molecular Biology of the Research Institute (Drs Michelson and Felberg) and the Oncology Unit of the Retina Service (Dr Shields) of the Wills Eye Hospital and Research Institute, Philadelphia.


Footnotes

Submitted for publication Dec 17, 1974.

Reprint requests to Wills Eye Research Institute, 1601 Spring Garden St, Philadelphia, PA 19130 (Dr Michelson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions
Keijser et al.
Br J Ophthalmol 2006;90:213-217.
ABSTRACT | FULL TEXT  

Evaluation of Metastatic Cancer to the Eye: Carcinoembryonic Antigen and Gamma Glutamyl Transpeptidase
Michelson et al.
Arch Ophthalmol 1977;95:692-694.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1976 American Medical Association. All Rights Reserved.